PMN Stock — ProMIS Neurosciences Inc. Common Shares (ON): Cash, EV, Pipeline

Share price

$14.01

Market cap

$125.6M

Cash

$53.5M

Enterprise value

$72.1M

Balance sheet

Cash	$53.5M
Debt	$0.0M
Net cash	$53.5M
Enterprise value	$72.1M
Basic shares	9.0M shares
Fully diluted shares	19.8M shares
Fully diluted market cap	$276.8M
Cash per share	$5.94

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PMN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	PMN310	Phase 1	Alzheimer Disease, Early Onset	Q1 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PMN310

Phase 1 · Active Modality: monoclonal antibody

Target misfolded amyloid-beta oligomers

Partnerships University of British Columbia (UBC): license to EpiSelect computational algorithm for misfolded-protein modeling

Indications

Alzheimer's disease (Phase 1)

Catalysts

— None

Status note Lead product candidate; antibody selectively targeting toxic misfolded oligomers of amyloid-beta (non-plaque binder). Phase 1b PRECISE-AD trial in Alzheimer's disease; FDA Fast Track designation.

PMN267

Preclinical · Active Modality: monoclonal antibody

Target misfolded TDP-43

Partnerships Collaboration with a partner with expertise in vectorization for intracellular delivery

Indications

Amyotrophic lateral sclerosis (ALS) (Preclinical)

Status note Second lead product candidate, targeting TDP-43-associated ALS (misfolded TDP-43).

PMN442

Preclinical · Active Modality: monoclonal antibody

Target misfolded alpha-synuclein

Indications

Dementia with Lewy bodies (DLB) (Preclinical)
Parkinson's disease (Preclinical)
Multiple system atrophy (MSA) (Preclinical)

Status note Selected lead candidate for synucleinopathies (DLB, PD, MSA), selectively targeting pathogenic forms of alpha-synuclein.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PMN310
Lead indication	Alzheimer Disease, Early Onset
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06750432	Phase 1	Active, not recruiting	Sponsor	PMN	—	Alzheimer Disease, Early Onset	Q1 2027

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for ProMis Neurosciences, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PMN — ProMIS Neurosciences Inc. Common Shares (ON)

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials